Skip to main navigation
Decibel Therapeutics logo
Menu Button

Top Menu

  • JOIN US
  • CONTACT US

Main Corporate Nav

  • About Us
  • The Need
  • Our Approach
  • Pipeline
  • Patients & Families
    • Genetic Testing
    • Patients and Families
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials
      • SEC Filings
    • Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Committee Composition
    • IR Resources
      • Email Alerts
      • Investor Contact
      • Investor FAQs
  • Join Us
  • Contact Us

Press Releases

March 14, 2023
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

more

February 16, 2023
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference

more

February 9, 2023
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

more

January 24, 2023
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

more

Shareholder Tools

Contact IR
Contact IR
Email Alerts
Email Alerts
Print Page
Print Page
RSS Feeds
RSS Feeds
Search
Search

© Decibel Therapeutics, Inc. 2023. All rights reserved.

  • Privacy Notice
  • Terms of Use
  • Twitter
  • LinkedIn

Main Corporate Nav

  • About Us
  • The Need
  • Our Approach
  • Pipeline
  • Patients & Families
    • Genetic Testing
    • Patients and Families
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials
      • SEC Filings
    • Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Committee Composition
    • IR Resources
      • Email Alerts
      • Investor Contact
      • Investor FAQs
  • Join Us
  • Contact Us